Our team is developing enzymatic solutions that aim to enhance nutritional care for tube-fed patients. Learn more about our innovative approach to improving patient outcomes: https://lnkd.in/dt28RbpP
Alcresta Therapeutics
医疗设备制造业
Newton，MA 2,728 位关注者
Fulfilling potential: With the Science of Enzymes
关于我们
Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 1 year and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by Linden Capital Partners and HealthQuest Capital.
- 网站
-
http://www.alcresta.com
Alcresta Therapeutics的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 51-200 人
- 总部
- Newton，MA
- 类型
- 私人持股
- 创立
- 2011
地点
-
主要
获取路线
One Newton Executive Park
Suite 100
US，MA，Newton，02462
Alcresta Therapeutics员工
动态
-
🎙️ Check out the 2nd episode in ASPEN’s Podcast Series on Fat Malabsorption in Disease States supported by Alcresta. This 2nd episode features Amy Berry, MS, RD, focusing on exocrine pancreatic insufficiency and management with pancreatic exocrine replacement therapy. Stream it here: https://lnkd.in/eYeqWawS
-
Have you registered yet? There’s still time to hear from your peers on Tuesday, April 15th at 12:00pm CST for a RELiZORB (iMMOBILIZED lipase) case study on improving fat absorption in tube feeding. Register at https://lnkd.in/e48-g4ai RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE is indicated for use in pediatric patients (ages 1 year and above) and adult patients to hydrolyze fats in enteral formula. RELiZORB is for use with enteral feeding only; do not connect to intravenous or other medical tubing. Medications should not be administered through RELiZORB. For more information and full safety information, visit www.relizorb.com.
-
-
Our team is excited to exhibit at the Oncology Nursing Society's 50th Annual #ONSCongress in Denver this week! Visit us at booth 3067 to connect, explore the latest advancements in symptom management and care delivery, and discover how we’re working to improve nutritional outcomes for individuals with GI cancers and other rare diseases. #CancerCare #OncologyNursing #Exhibiting #InnovationInCare
-
-
Our partner, The Oley Foundation, is committed to supporting individuals who rely on home IV nutrition or #tubefeeding. We’re inspired by their ongoing efforts to improve lives through advocacy, education, community, and innovation. Learn more: https://lnkd.in/epN-X-Ds #NutritionalCare #Nutrition
-
Our Associate Director of Commercial Strategy & Analytics, Eric M., shares the personal motivation behind his work at Alcresta as he answers the question, "Why Alcresta?" Thanks for sharing, Eric! Your passion for improving nutritional outcomes for the enteral feeding community is truly inspiring. #WhyAlcresta #EmployeeSpotlight
-
-
🎙️Check out ASPEN’s NEW Podcast Series on Fat Malabsorption in Disease States supported by Alcresta. This ASPEN podcast series is based on the Nutrition in Clinical Practice Supplement titled ‘Fat Malabsorption in Disease States’ published in April 2024. This podcast series provides an in-depth look at the latest understanding of fat malabsorption in various disease states and was developed to educate clinicians on the current evidence in the management of this condition. This 1st episode features Dr. Endashaw Omer, MD, MPH, focusing on physiology, pathophysiology, and diagnosis of fat malabsorption. Stream it here: https://lnkd.in/ernRphgJ
-
Hear from your peers—Join us on Tuesday, April 15th at 12:00pm CST for a RELiZORB (immobilized lipase) case study on improving fat absorption in tube feeding. Moderated by Kelly Tappenden, PhD, RD of the University of Utah and featuring Valeria Cohran, MD, MS of The Ann & Robert H. Lurie Children’s Hospital of Chicago. Register at https://lnkd.in/e48-g4ai RELiZORB® (iMMOBILIZED LIPASE) CARTRIDGE is indicated for use in pediatric patients (ages 1 year and above) and adult patients to hydrolyze fats in enteral formula. RELiZORB is for use with enteral feeding only; do not connect to intravenous or other medical tubing. Medications should not be administered through RELiZORB. For more information and full safety information, visit www.relizorb.com.
-
-
Join our team this week in Columbus, Ohio, for the American Society for Parenteral & Enteral Nutrition (ASPEN) 2025 Nutrition Science & Practice Conference! This exciting event brings together professionals from across the industry to explore the latest advancements in clinical nutrition. We look forward to networking with fellow experts in the field, attending insightful sessions, and discovering innovative solutions to enhance patient care. We hope to see you there! #ASPEN25
-
-
Today is Registered Dietitian Nutritionist Day, an opportunity to recognize the crucial role Registered Dietitian Nutritionists (RDNs) play in promoting nutritional health and wellness. Their expertise in nutrition empowers individuals to make informed choices that positively impact their lives. #RegisteredDietitianNutritionistDay #NationalNutritionMonth #NutritionalCare #Nutrition
-